Study | Phase | Treatment line | Arm | Patients | PD-L1+ patients | Age, median (range) | Male (%) | ECOG (%) | Intervention | |
---|---|---|---|---|---|---|---|---|---|---|
0–1 | 2 | |||||||||
Kojima 2020 [15] KEYNOTE-181 | III | 2 | PD-1 inhibitor | 198 | 85 | NA | NA | NA | NA | Pembrolizumab 200 mg Q3W |
Chemotherapy | 203 | 82 | NA | NA | NA | NA | Investigator choice chemotherapy | |||
Kato 2019 [16] ATTRACTION-3 | III | 2 | PD-1 inhibitor | 210 | 101 | 64 (57, 69) | 179 (85%) | 210 (100%) | 0 (0%) | Nivolumab 240 mg Q2W |
Chemotherapy | 209 | 102 | 67 (57, 72) | 185 (89%) | 209 (100%) | 0 (0%) | Investigator choice chemotherapy | |||
Huang 2020 [17] ESCORT | III | 2 | PD-1 inhibitor | 228 | 93 | 60 (54, 65) | 208 (91%) | 228 (100%) | 0 (0%) | Camrelizumab 200 mg Q2W |
Chemotherapy | 220 | 98 | 60 (54, 65) | 192 (87%) | 220 (100%) | 0 (0%) | Investigator choice chemotherapy | |||
Xu 2020 [18] ORIENT-2 | II | 2 | PD-1 inhibitor | 95 | NA | NA | NA | 95 (100%) | 0 (0%) | Sintilimab 200 mg Q3W |
Chemotherapy | 95 | NA | NA | NA | 95 (100%) | 0 (0%) | Investigator choice chemotherapy | |||
Ajani 2021 [19] RATIONALE 302 | III | 2 | PD-1 inhibitor | 256 | NA | NA | NA | 256 (100%) | 0 (0%) | Tislelizumab 200 mg Q3W |
Chemotherapy | 256 | NA | NA | NA | 256 (100%) | 0 (0%) | Investigator choice chemotherapy |